Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 4 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Multiple Myeloma 1Hematologic Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Leflunomide × Clear all
NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
Breast

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04532372 2024-07-03

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

City of Hope Medical Center

Phase 1/2 Completed
2 enrolled 7 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT02509052 2023-10-10

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
12 enrolled 21 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡